Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)

For patients with metastatic renal cell carcinoma who received tyrosine kinas inhibitor (TKI) induction therapy, a switch to nivolumab for maintenance therapy had lower efficacy than TKI continuation. Our study indicates that patients who respond to a TKI should continue treatment. Future studies should explore the role of biomarkers to guide therapy selection.